Open AccessSPECIAL CONSIDERATION OF ANTIBACTERIAL THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Author(s) -
И. В. Демко,
Е. А. Собко,
И. А. Соловьева,
Olha Ishchenko,
А. Ю. Крапошина,
Н. В. Гордеева,
Svetlana Chubarova,
Marina Mamaeva
Publication year - 2016
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 6
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2016-26-5-618-622
Subject(s) - medicine , copd , exacerbation , intensive care medicine , acute exacerbation of chronic obstructive pulmonary disease , sputum , antibiotics , adverse effect , tuberculosis , pathology , microbiology and biotechnology , biology
Current guidelines consider timely diagnosis, treatment and prevention of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) as an important goal of the management of patients with COPD. Frequent AECOPD accelerate lung function declining and decrease quality of life. AECOPD are essentially associated with worsening of the mucociliary clearance and are caused unfrequently by respiratory infection. A case report is included in the article. A male with AECOPD was treated with inhalation therapy without systemic antibiotics. Thiamphenicol, glycinate acetylcysteinate (Fluimucil antibiotic IT) was used along with the standard therapy of AECOPD due to its antibacterial, antioxidant and mucolytic activity. Dyspnea, sputum expectoration, physical tolerance of the patient and rhonchi on auscultation improved in 3 days of treatment. The authors have concluded that administration of this drug allowed reduction drug load and decrease a risk of adverse events associated with systemic drug exposure.